Please provide your email address to receive an email when new articles are posted on . Data presented at the International Congress on Schizophrenia Research indicated a higher dose of Aristada may ...

Alkermes announced positive top-line results from its pharmacokinetics trial of Aristada (aripiprazole lauroxil extended-release injectable suspension). Alkermes announced positive top-line results ...

About ARISTADA® ARISTADA is an injectable atypical antipsychotic with one-month and six-week dosing options for the treatment of schizophrenia. ARISTADA is administered by a healthcare professional.

The FDA approval of Aristada for use every two months provides more dosing flexibility and may encourage more doctors to prescribe it. Nowadays, Alkermes has focused a lot of its attention on crafting ...

About ARISTADA® ARISTADA is an injectable atypical antipsychotic with one-month and six-week dosing options for the treatment of schizophrenia. ARISTADA is administered by a healthcare professional.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA today approved 2-month Aristada, an ...

The FDA (Food and Drug Administration) approved Aristada (Aripiprazole Lauroxil) partly on account of the drug’s clinical trials, which proved that patients using the treatment saw reductions in the ...

Alkermes plc (NASDAQ:ALKS) announced that the FDA has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. The new two month ...

Aripiprazole lauroxil extended-release injectable suspension 675mg/2.4mL; for IM inj. In combination with oral aripiprazole, for initiation (or reinitiation after a missed dose) of Aristada when used ...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA™ (aripiprazole lauroxil) extended-release injectable ...

-- Retail Pharmacies, Including 900 Albertsons Locations, Added to the Provider Locator to Provide Injections of ARISTADA and VIVITROL; Additional Programs In Place to Deliver Support and Financial ...

Alkermes plc. ALKS announced that the FDA has approved Aristada Initio (aripiprazole lauroxil) extended-release product for the treatment of schizophrenia in adults. The approval of Aristada Initio ...